Analysis of the structure and properties of dextran produced by Weissella confusa

Du, Renpeng; Pei, Fangyi; Kang, Jie; Zhang, Wen; Wang, Shuo; Ping, Wenxiang; Ling, Hongzhi; Ge, Jingping

doi:10.1016/j.ijbiomac.2022.02.038

Cited by 26 publications

(26 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To calculate the Mw of lyEPS, the molecular weight was calculated from a calibration curve using various pullulan (Mw: 180 Da, 667 Da, 6.3 kDa, 9.8 kDa, 22 kDa, 49.4 kDa, 110 kDa, 201 kDa, 334 kDa, and 642 kDa) as standard material, as described previously [ 1 ]. The GPC was performed by injecting a solution of lyEPS (3 mg/mL; 50 μL) eluted with 0.1 M NaNO3 at 40 °C at a flow rate of 1 mL/min [ 53 ]. The Mw of lyEPS was estimated to be 1.01 × 10 5 Da, and the GPC results of lyEPS revealed only one fraction ( Figure 3 e).…”

Section: Resultsmentioning

confidence: 99%

“…The Mw of lyEPS was assessed by gel permeation chromatography (GPC) (HLC-8420; Tosoh, Japan) with a TSKgel G2500PW XL column and estimated using an RI detector. lyEPS solution (3 mg/mL; 50 μL) was injected and eluted with 0.1 M NaNO3 at 40 °C at a flow rate of 1 mL/min [ 53 ]. The Mw of the sample was calculated using EcoSEC Elite-WS software based on the peak time.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Characteristics and Biological Activity of Exopolysaccharide Produced by Lysobacter sp. MMG2 Isolated from the Roots of Tagetes patula

Kim

Chhetri

et al. 2022

Microorganisms

View full text Add to dashboard Cite

In the present study, exopolysaccharide (EPS) produced by Lysobacter sp. MMG2 (lyEPS) was characterized and purified. The lyEPS-producing strain Lysobacter sp. MMG2 was isolated from the roots of Tagetes patula. When lyEPS was produced in tryptic soy broth with 1% glucose and the lyophilized powder was measured, the yield was found to be 0.67 g/L. The molecular weight (Mw) of lyEPS was 1.01 × 105 Da. Its monosaccharide composition includes 84.24% mannose, 9.73% glucose, 2.55% galactose, 2.77% arabinose, 0.32% xylose, and 0.03% rhamnose. Scanning electron microscopy (SEM) revealed that lyEPS has various round and rough surfaces. Fourier-transform infrared (FTIR) analysis identified its carbohydrate polymer functional groups. Moreover, thermogravimetric analysis of lyEPS revealed two events of mass loss: the first was water loss, which resulted in 3.97% mass loss and the second event occurred at approximately 212 °C. lyEPS could inhibit biofilm-producing pathogenic bacteria without any antimicrobial activity. Furthermore, lyEPS at a concentration of 4 mg/mL could exhibit potent 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical-scavenging activity (89.25%). These results indicate that lyEPS could be a promising candidate for industrial development if its biological activity is further explored.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Characteristics and Biological Activity of Exopolysaccharide Produced by Lysobacter sp. MMG2 Isolated from the Roots of Tagetes patula

Kim

Chhetri

et al. 2022

Microorganisms

View full text Add to dashboard Cite

show abstract

“…DEX is a polysaccharide which is biosynthesized intra- or extra-cellularly (endopolysaccharide—ENS or exopolysaccharide—EPS) by several microorganisms such as Leuconostoc mesenteroides [ 31 ], Leuconostoc dextranicum [ 45 ], Lactobacillus brevis , Streptococcus mutants and Weissella confusa [ 33 , 35 , 46 ], Acetobacter capsulatus , renamed Gluconobacter oxydans and Acetobacter viscous , yeasts and moulds (e.g., Rhizopus spp.) [ 36 ].…”

Section: Dex Obtained By Biosynthesis From Lab Fermentationmentioning

confidence: 99%

“…An important aspect of obtaining high amounts of bio-polymers is the fermentation conditions. Depending on the composition of the culture medium and the strain type, DEX can be obtained with a low or high molecular weight (over 150 kDa) [ 35 , 46 ]. Dextransucrase (1,6-α-D-glucan 6-α-glucosyltransferase, E.C.…”

Section: Dex Obtained By Biosynthesis From Lab Fermentationmentioning

confidence: 99%

“…Many research groups have chemically modified DEX by introducing functional groups into the molecule through cross-linking reactions, therefore improving mechanical strength and drug-loading ability [ 9 , 41 ] and increasing the number of compound classes that can be obtained. Furthermore, DEX has been shown to have metal chelating activity [ 46 ] and antioxidant properties [ 59 ], as well as antitumour activity by regulating apoptosis and autophagy [ 61 ].…”

Section: Biomedical Applications Of Modified Dexmentioning

confidence: 99%

See 1 more Smart Citation

Dextran Formulations as Effective Delivery Systems of Therapeutic Agents

Petrovici¹,

Pinteala²,

Simiónescu

2023

Molecules

View full text Add to dashboard Cite

Dextran is by far one of the most interesting non-toxic, bio-compatible macromolecules, an exopolysaccharide biosynthesized by lactic acid bacteria. It has been extensively used as a major component in many types of drug-delivery systems (DDS), which can be submitted to the next in-vivo testing stages, and may be proposed for clinical trials or pharmaceutical use approval. An important aspect to consider in order to maintain high DDS’ biocompatibility is the use of dextran obtained by fermentation processes and with a minimum chemical modification degree. By performing chemical modifications, artefacts can appear in the dextran spatial structure that can lead to decreased biocompatibility or even cytotoxicity. The present review aims to systematize DDS depending on the dextran type used and the biologically active compounds transported, in order to obtain desired therapeutic effects. So far, pure dextran and modified dextran such as acetalated, oxidised, carboxymethyl, diethylaminoethyl-dextran and dextran sulphate sodium, were used to develop several DDSs: microspheres, microparticles, nanoparticles, nanodroplets, liposomes, micelles and nanomicelles, hydrogels, films, nanowires, bio-conjugates, medical adhesives and others. The DDS are critically presented by structures, biocompatibility, drugs loaded and therapeutic points of view in order to highlight future therapeutic perspectives.

show abstract

Polymer–drug and polymer–protein conjugated nanocarriers: Design, drug delivery, imaging, therapy, and clinical applications

Guo,

2024

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Polymer–drug conjugates and polymer–protein conjugates have been pivotal in the realm of drug delivery systems for over half a century. These polymeric drugs are characterized by the conjugation of therapeutic molecules or functional moieties to polymers, enabling a range of benefits including extended circulation times, targeted delivery, controlled release, and decreased immunogenicity. This review delves into recent advancements and challenges in the clinical translations and preclinical studies of polymer–drug conjugates and polymer–protein conjugates. The design principles and functionalization strategies crucial for the development of these polymeric drugs were explored followed by the review of structural properties and characteristics of various polymer carriers. This review also identifies significant obstacles in the clinical translation of polymer–drug conjugates and provides insights into the directions for their future development.This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

show abstract

Analysis of the structure and properties of dextran produced by Weissella confusa

Cited by 26 publications

References 43 publications

Characteristics and Biological Activity of Exopolysaccharide Produced by Lysobacter sp. MMG2 Isolated from the Roots of Tagetes patula

Characteristics and Biological Activity of Exopolysaccharide Produced by Lysobacter sp. MMG2 Isolated from the Roots of Tagetes patula

Dextran Formulations as Effective Delivery Systems of Therapeutic Agents

Polymer–drug and polymer–protein conjugated nanocarriers: Design, drug delivery, imaging, therapy, and clinical applications

Contact Info

Product

Resources

About